Scarica l'app Stockscreener
5.26
0.77%
0.04
Dopo l'orario di chiusura:
5.26
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda Pharmaceuticals Inc (VNDA) (Q2 2026) Earnings Call Highlig - GuruFocus
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - marketbeat.com
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - marketbeat.com
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - marketbeat.com
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada
VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals Inc (VNDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA - marketbeat.com
Vanda Pharmaceuticals Inc (VM4.DU) insider ownership and holdings - Yahoo Finance Australia
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Vanda Pharmaceuticals (VNDA) Stock Holds Steady As Losses Deepen - Sahm
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda Posts Wider Q2 Loss as Spending Surges; Revenue Dips 4% on Hetlioz Decline - finance.biggo.com
Vanda Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Vanda Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Vanda misses Q2 2026 estimates as losses widen - Investing.com
Is Vanda Pharmaceuticals (VNDA) Facing Growth Challenges After Q - GuruFocus
Vanda Pharmaceuticals (NASDAQ:VNDA) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPS - MarketBeat
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Inc. Reiterates Revenue Guidance for the Full-Year 2026 - marketscreener.com
Vanda Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
VANDA PHARMACEUTICALS ($VNDA) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results - AOL.com
Vanda Pharmaceuticals Q2 loss widens on lower sales, higher costs - TradingView
BRIEF-Vanda Pharmaceuticals Q2 EPS USD -1.04 - TradingView
Vanda Pharmaceuticals Inc expected to post a loss of 59 cents a shareEarnings Preview - TradingView
Vanda investors can hear its Q2 update Aug. 5 at 4:30 p.m. - Stock Titan
Vanda Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
$5.23 | Vanda Pharmaceuticals Inc. Common Stock (VNDA) Stock Price Today - Binance
Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:+0.100 - TradingKey
Vanda Pharmaceuticals (VNDA) to Post Earnings on Thursday - marketbeat.com
Vanda's NDA Rejection Challenge Can't Be Heard At DC Court - Law360
ETFs Investing in Vanda Pharmaceuticals Inc. Stocks - TradingView
Licensable picture: Vanda Pharmaceuticals Athens OpenDay 5 - reutersconnect.com
Vanda PharmaceuticalsRisks Rising, Rewards DwindlingWhy I'm Downgrading To Hold - Seeking Alpha
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular PsoriasisA Milestone Recognition of GPP as a Distinct Rare Disease in Europe - Sahm
Watch VANDA Pharmaceuticals Athens Open / Grandstand (Doubles) - Disney Plus
Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP - TradingView
Vanda Pharmaceuticals (VNDA) Receives Orphan Drug Designation fo - GuruFocus
EMA Panel Recommends First EU Orphan Designation for Rare Skin Disease - Stock Titan
Vanda shifts Nereus marketing into high gear with Schumacher IndyCar sponsorship - Fierce Pharma
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):